Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: A randomized, open-labeled trial

Eun Ho Kang, In Soo Lee, Sang Keun Chung, Sang Yeol Lee, Eui Jung Kim, Jin Pyo Hong, Kang Seob Oh, Jong Min Woo, Seonwoo Kim, Joo Eon Park, Bum Hee Yu

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Somatic symptoms are often important in the treatment of major depressive disorder (MDD). The aim of this open-labeled trial was to examine the efficacy of mirtazapine for the treatment of MDD with clinically significant somatic symptoms, as compared with venlafaxine. A total of 126 patients with MDD (score ≥ 18 on the Hamilton Rating Scale for Depression-17) were included in both the intent-to-treat (n = 73 in the mirtazapine group and n = 53 in the venlafaxine group) and completer analysis (n = 51 and n = 37, respectively). After treatment, both treatment groups showed similar improvements in depressive symptoms. Repeated measures analysis of variance for the intent-to-treat population revealed that there were no significant differences in mean change of the Symptom Check List-90-Revised (SCL-90-R) somatization subscores between the two groups. For completers, there was a significant time × treatment interaction in the SCL-90-R somatization subscores, but the differences between the two groups at endpoint did not reach statistical significance in post-hoc analysis. In conclusion, this study suggests that overall efficacies of mirtazapine and venlafaxine are similar for the treatment of overall symptoms in MDD, and both drugs may be useful for the treatment of somatic symptoms in MDD patients.

Original languageEnglish
Pages (from-to)118-123
Number of pages6
JournalPsychiatry Research
Volume169
Issue number2
DOIs
StatePublished - 30 Sep 2009

Keywords

  • Major depressive disorder
  • Mirtazapine
  • Somatic symptom
  • Treatment response
  • Venlafaxine

Fingerprint

Dive into the research topics of 'Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: A randomized, open-labeled trial'. Together they form a unique fingerprint.

Cite this